PFM
ABVX icon

Privium Fund Management’s Abivax ABVX Stock Holding History

Privium Fund Management’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-30,412
Closed -$2.58M – 58
2025
Q3 		$2.58M Buy
+30,412
New +$1.86M 0.46% 26

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Privium Fund Management's ABVX Position: Q4 2025 in Review

Privium Fund Management sold out of Abivax (ABVX) in Q4 2025, closing a stake of 30,412 shares — an estimated $2.58M sold.

Privium Fund Management first reported a position in ABVX in Q3 2025 and held it in 1 quarter. The position peaked at $2.58M in Q3 2025. 247 funds tracked by Wall St. Rank hold ABVX as of Q4 2025.

  • Privium Fund Management reported no remaining Abivax position as of Q4 2025 after selling out during the quarter.
  • Privium Fund Management sold 30,412 Abivax shares in Q4 2025, an estimated $2.58M.
  • Privium Fund Management first reported a position in Abivax in Q3 2025 and held it in 1 quarter.
  • Privium Fund Management's Abivax position peaked at $2.58M in Q3 2025.
  • 247 funds tracked by Wall St. Rank held Abivax as of Q4 2025.

Based on Privium Fund Management's 13F filing for Q4 2025, filed 3 Feb 2026.